Study supports sequencing in kids with cancer


General Medical Sciences

Genome analysis Photo courtesy of the National Institute of

SAN DIEGO—Comprehensive next-generation sequencing is both feasible and clinically useful in pediatric cancer patients, a new study suggests.

Researchers sequenced samples from 253 pediatric cancer patients and found that, in 79% of cases, there was at least one finding that could help guide care.

Scott Newman, PhD, of St. Jude Children’s Research Hospital in Memphis, Tennessee, presented these findings at the American Society of Human Genetics (ASHG) 2018 Annual Meeting (abstract 52).

The researchers conducted whole-genome, exome, and transcriptome sequencing of the patients’ tumors, as well as sequencing non-cancerous tissues from the same patients.

Of the 253 patients studied, 123 had hematologic malignancies.

The researchers found a mean of four pathogenic or likely pathogenic variants per patient (range, 0-18). This included prognostic (21.8%) and diagnostic (15.1%) variants as well as variants that could be targeted therapeutically (6.8%).

In all, 79% of the patients had at least one variant that was targetable, diagnostic, or prognostic. And test results were available within about 40 days, quickly enough that they could be used to guide care.

“With results available in a clinically relevant time frame, and pricing becoming increasingly comparable to the radiology and pathology tests, WGS [whole-genome sequencing] is becoming more accessible to pediatric oncology patients,” Dr. Newman said.

This work was part of the Genomes for Kids study (G4K), an effort to understand how best to use genetic data for pediatric cancer diagnosis and treatment. St. Jude has compiled the information from G4K into a publicly accessible online database.

The researchers have continued to perform sequencing on current patients, and, since the original study ended, have successfully used this method on roughly 300 additional patients. The team plans to continue studying sequencing methods in hopes of producing clinically applicable data more quickly.

G4K was sponsored by St. Jude.

Recommended Reading

Optimizing use of TKIs in chronic leukemia
MDedge Hematology and Oncology
FDA offers guidance on MRD assessment in blood cancer trials
MDedge Hematology and Oncology
Ibrutinib plus obinutuzumab gets priority review in CLL/SLL
MDedge Hematology and Oncology
Researchers consider R/R ALL drugs in the first-line setting
MDedge Hematology and Oncology
Adoptive T-cell therapy treats PML
MDedge Hematology and Oncology
‘Intense’ end-of-life care may be common in HSCT recipients
MDedge Hematology and Oncology
Dataset could reveal better therapies for AML
MDedge Hematology and Oncology
FDA issues draft guidance on MRD
MDedge Hematology and Oncology
Bacteremic sepsis in ALL tied to neurocognitive dysfunction
MDedge Hematology and Oncology
The challenges of diagnosing CMML
MDedge Hematology and Oncology